Exploring the Benefits of Preoperative Daromun Therapy in Melanoma Patients
A recent study has revealed the positive impact of administering Daromun before surgery on relapse-free survival (RFS) in patients with locally advanced melanoma. Comparing outcomes between patients who received Daromun prior to surgery and those who underwent immediate surgery alone, it was evident that the former experienced a significant increase in RFS.
Patients treated with Daromun before surgery exhibited a median RFS that was more than double that of patients who had immediate surgery, with a duration of 16.7 months compared to 6.8 months. Over a 3-year period, consistent analysis demonstrated the efficacy of Daromun, with both independent reviews and investigator assessments validating the positive results.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
